Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 20/20 | 0.77 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.77 |
| ▸ | KAT2A | Q92830 | 2/20 | 0.77 |
| ▸ | BPTF | Q12830 | 2/20 | 0.77 |
| ▸ | BRD1 | O95696 | 1/20 | 0.77 |
| ▸ | ACHE | P22303 | 1/20 | 0.77 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.77 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.77 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.77 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25445772 | 0.88 | KAT2B (0.75) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL23682853 | 0.87 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL23682859 | 0.87 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL26216685 | 0.87 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830606 | 0.86 | KAT2B (0.77) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830536 | 0.85 | KAT2B (0.76) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830503 | 0.85 | KAT2B (0.76) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830559 | 0.85 | KAT2B (0.79) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830872 | 0.85 | KAT2B (0.76) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830560 | 0.83 | KAT2B (0.73) | KAT2BBRD9KAT2ABPTFBRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | TP53, TP53BP1, MDM2 | KAT2B 3184/4885BRD9 2018/4885KAT2A 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.